Investigational drug · Phase 3
JKN2401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease (COPD).
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "JKN2401"
First trial start
2026
Mar 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JKN2401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "JKN2401" as an intervention, largest first.
- A Phase 3 Trial of JKN2401 Injection in COPDPivotal-lookingNot yet recruiting
Joincare Pharmaceutical Group Industry Co., LtdIndustry
NCT07330310 · 888 participants (planned) · Start Mar 2026 · Primary completion Sep 2027
Drug: JKN2401 Injection · For: Chronic Obstructive Pulmonary Disease (COPD)
- A Phase 2 Trial of JKN24011 in COPDPivotal-lookingCompleted
Joincare Pharmaceutical Group Industry Co., LtdIndustry
NCT07440524 · 215 participants · Start Aug 1, 2024 · Primary completion Apr 2, 2026
Drug: JKN24011 · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.
Song GQ, Chen B, He TL, et al. · Front Immunol 2026
Also in development for Chronic Obstructive Pulmonary Disease (COPD)
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- HSK39004 Dry SimulantPhase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- PRA-216Phase 22 trials
Prana Therapies Inc · Chronic Obstructive Pulmonary Disease (COPD), Mild to Moderate Asthma
- AZD6793Phase 21 trial
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD)
- EXPD-101FXS7553Phase 21 trial
Expedition Therapeutics, Inc · Chronic Obstructive Pulmonary Disease (COPD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.